Patents Represented by Attorney, Agent or Law Firm Steve T. Zelson
  • .beta.-1,4-galactanase and a DNA sequence
    Patent number: 5474922
    Abstract: The present invention relates to .beta.-1,4-galactanase derived from A. aculeatus which have (a) a pH-optimum between 3.0 and 5.0, (b) an isoelectric point of 2.5-3.5, (c) a molecular weight of between 30,000 and 50,000, and (d) a temperature optimum between 10.degree. and 50.degree. C.
    Type: Grant
    Filed: July 15, 1993
    Date of Patent: December 12, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Kurt Dorreich, Henrik Dalboge, Jan M. Mikkelsen, Marcel Mischler, Flemming M. Christensen
  • Protease from Dendryphiella arenaria DSM 6260 or Dendryphiella salina DSM 6332, process for making it and use as detergent additive
    Patent number: 5472865
    Abstract: A protease obtainable from Dendryphiella arenaria DSM 6260 or Dendryphiella salina DSM 6332 is disclosed. The protease has a pl of approximately 9.1 as determined by isoelectric focusing, a molecular weight of approximately 18-20 kD as determined by SDS-PAGE, is active towards haemoglobin, casein, skimmed milk, and Suc-Ala-Ala-Pro-Phe-pNA and has immunochemical properties identical to those of a protease obtained from Dendryphiella arenaria DSM 6260 or Dendryphiella salina DSM 6332. A process for its production, use in a detergent composition and as a detergent additive are disclosed.
    Type: Grant
    Filed: September 28, 1993
    Date of Patent: December 5, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Kim B. Pedersen, Margrethe Christiansen, Poul Lindegaard
  • 2,3,4,5-tetrahydro-1H-3-benzazepines
    Patent number: 5470850
    Abstract: 2,3,4,5-Tetrahydro-1H-3-benzazepines having the general formula ##STR1## wherein R.sup.1 is Cl or Br; R.sup.3 and R.sup.4 are hydrogen, halogen, CF.sup.3, CN, NO.sub.2, or NH.sub.2.The compounds are useful in treatment of certain disorders in the central nervous system.
    Type: Grant
    Filed: May 6, 1994
    Date of Patent: November 28, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Christian Foged, Rolf Holweg, Erik Nielsen
  • Detergent enzymes
    Patent number: 5468416
    Abstract: This inventions is in the field of detergent enzymes. More specifically, the invention relates to the use of proteases from fungi of the genus Verticillium for detergent purposes.
    Type: Grant
    Filed: February 8, 1994
    Date of Patent: November 21, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Dorrit A. Aaslyng, Claus Dambmann, Shamkant A. Patkar
  • Alkaline protease Bacillus sp. JP 395, method of making and detergent compositions
    Patent number: 5466594
    Abstract: An alkaline protease from a strain of Bacillus sp. JP 395 has been isolated. The protease has a mass of about 30 kDa as determined by SDS-PAGE, a pH optimum of about 9-11, a temperature optimum of about 50.degree.-65.degree. C., and an isoelectric point above 9.5. The protease is inhibited by PMSF (phenylmethylsulfonylfluoride), but not by EDTA or soybean protein inhibitor. The protease is prepared by growing this strain of bacillus in a suitable media and recovering the protease. The protease has been formulated in detergents and is stable at 40.degree. C. for 60 minutes in these detergents under wash conditions in the presence or absence of bleaches such as perborate.
    Type: Grant
    Filed: September 23, 1993
    Date of Patent: November 14, 1995
    Assignee: Nove Nordisk A/S
    Inventors: Helle Outtrup, Claus Dambmann, Margrethe Christiansen, Dorrit A. Aaslyng
  • Syringe system
    Patent number: 5462535
    Abstract: An insulin injection system comprises a pen shaped syringe with a cartridge containing insulin, and an injection needle. The needle is a G30 needle and the insulin is a type which may freely flow through a G30 needle. When the insulin is the type comprising suspended crystals the maximal dimension of any crystal is 15 .mu.m.
    Type: Grant
    Filed: October 14, 1994
    Date of Patent: October 31, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Frits F. Bonnichsen, Peter N. Jorgensen
  • Method of producing IGF-1
    Patent number: 5459052
    Abstract: Ala-Glu-IGF-I is a novel compound which exerts IGF-I activity and is a precursor for the preparation of IGF-I. Ala-Glu-IGF-I may by converted to IGF-I by renaturation after recombinant production in E. coli under specified conditions and then cleaving Ala-Glu from the IGF-I.
    Type: Grant
    Filed: July 2, 1993
    Date of Patent: October 17, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Lars Skriver, Kim R. Hejn s, Henrik Dalboge
  • Enzymes with xylanolytic activity
    Patent number: 5457045
    Abstract: This invention relates to novel enzymes possessing xylanolytic activity. More specifically, the invention relates to novel xylanases obtainable from strains of Bacillus pumilus, a process for their preparation, and the use of these xylanases for treatment of lignocellulosic pulp.
    Type: Grant
    Filed: February 2, 1993
    Date of Patent: October 10, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Lisbeth Anker, Henrik Bisgard-Frantzen, Torben Halkier
  • Enzyme capable of degrading cellullose or hemicellulose
    Patent number: 5457046
    Abstract: A cellulose- or hemicellulose-degrading enzyme which is derivable from a fungus other than Trichoderma or Phanerochaete, and which comprises a carbohydrate binding domain homologous to a terminal A region of Trichoderma reesei cellulases, which carbohydrate binding domain amino acid sequence (.alpha.) or a subsequence thereof capable of effecting binding of the enzyme to an insoluble cellulosic or hemicellulosic substrate.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: October 10, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Helle F. Woldike, Fred Hagen, Carsten Hjort, Sven Hastrup
  • Method and device for in vivo measuring the concentration of a substance in the blood
    Patent number: 5452716
    Abstract: In vivo measurement of the concentration of a substance in the blood, e.g. glucose, despite varying concentrations of interfering components, e.g. protein and fat, by measuring the absorption of infra red light at a pair of selected wavelengths in the range 1-40 .mu.m for each of the substance and the components one being a measuring wavelength at which the substance or component show a specific absorption and another being a reference wavelength at which the substance or component shows a low absorption, at least one wavelength being selected from the range 1-10 .mu.m. The absorption is measured using a detector providing a computable electric signal corresponding to the absorbed amount of infra red radiation at the respective wavelengths. The electric signals are used to calculate the concentration of the substance taking into account the absorption caused by the interfering components.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: September 26, 1995
    Assignee: Novo Nordisk A/S
    Inventor: Vaughan Clift
  • Lipase containing liquid pre-spotter and use of such pre-spotter
    Patent number: 5447649
    Abstract: The pre-spotter comprises a surfactant free liquid pre-spotter containing alcohol, water and an effective amount of lipase. This pre-spotter is simple and it exhibits an improved fat and oil removing effect and an improved lipase stability.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: September 5, 1995
    Assignee: Novo Nordisk A/S
    Inventor: Erik Gormsen
  • Bleaching detergent composition containing acylated sugar bleach activators
    Patent number: 5431849
    Abstract: Esters of monosaccharides and their lower alkyl glycosides are effective both as suffactants and as bleach activators (peracid precursors). The compounds are non-toxic and biodegradable. They act as nonionic suffactants and are effective in soil removal from textiles, e.g. of fatty soiling. In the presence of a hydrogen peroxide source, the sugar derivatives are perhydrolyzed during the washing process to form long-chain peracid. This enhances the bleaching effect, especially on hydrophobic stains.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: July 11, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Ture Damhus, Ole Kirk, Frederick E. Hardy
  • C2,N.sup.6 -disubstituted adenosine derivatives
    Patent number: 5432164
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio, or C.sub.1-6 -alkylamino; andR.sup.1 is selected from N-bonded heterocycles.The compound with the greatest ability to discriminate between the A1 and A2 adenosine receptors is 2-chloro-N-[4-phenoxy-1-piperidinyl]adenosine. These adenosine derivatives are useful as anti-convulsants.
    Type: Grant
    Filed: October 20, 1992
    Date of Patent: July 11, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Lars J. S. Knutsen, Jesper Lau
  • 2-chloro-N.sup.6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias
    Patent number: 5430027
    Abstract: Adenosine compounds having the following structure ##STR1## wherein X is halogen, perhalomethyl, acetamido, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino; andR.sup.1 is --NR.sup.2 R.sup.3 or YR.sup.4, wherein Y is oxygen or sulfur;R.sup.2 is phenyl, C.sub.1-6 -alkyl or substituted C.sub.1-6 -alkyl; andR.sup.4 is naphthyl, partly saturated naphthyl; optionally phenyl or phenoxy substituted C.sub.1-6 -alkyl wherein the phenyl and phenoxy substituents are also optionally substituted, or optionally phenyl or phenoxy substituted C.sub.3-8 -cycloalkyl and their pharmaceutically acceptable salts are useful in the treatment of myocardial and cerebral ischemias.
    Type: Grant
    Filed: May 14, 1993
    Date of Patent: July 4, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Lars J. S. Knutsen, Jesper Lau
  • Insulin compounds and compositions
    Patent number: 5430016
    Abstract: Novel insulin compounds having a desirably protracted insulin action and/or antigenicity are provided.The novel insulin compounds are represented by the formula II: ##STR1## wherein E individually represents Glu or a neutral amino acid residue which can be coded for by nucleotide sequences, N represents an amino acid residue which can be coded for by nucleotide sequences,T represents Thr or Arg,X represents Thr, Ser, Ala or OH, andY represents OR or NR.sup.1 R.sup.2, where R, R.sup.1 and R.sup.2 individually represents hydrogen or lower alkyl, but is not present when X represents OH.
    Type: Grant
    Filed: March 19, 1990
    Date of Patent: July 4, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Per Balschmidt, Finn B. Hansen
  • Heterocyclic compounds and their preparation and use
    Patent number: 5418240
    Abstract: The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: May 23, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Preben H. Olesen
  • Azabicyclo substituted oxa- or thia-diazole compounds
    Patent number: 5414009
    Abstract: The present invention relates to compounds ##STR1## where G is ##STR2## and Z is oxygen or sulfur and the remaining variables are as defined in the Specification. The compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    Type: Grant
    Filed: January 4, 1993
    Date of Patent: May 9, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Preben H. Olesen, Per Sauerberg
  • Fungicidally active compounds
    Patent number: 5409951
    Abstract: Novel compounds of formula I ##STR1## wherein R.sup.1 is independently hydrogen, hydroxy, alkyl with 1 to 6 carbon atoms, acyloxy groups with 1 to 6 carbon atoms, alkyloxy with 1 to 6 carbon atoms or from 1 to 5 sugar moleties; and R.sup.2 is independently hydrogen, or alkyl with 1 to 6 carbon atoms.The compounds are producible by aerobic cultivation on suitable nutrient media under suitable conditions of a strain of the fungus Ascochyta sp., subsequent recovery of the active component from the fermentation medium, and optionally modifying the active compound to obtain a compound of the desired formula I.Disclosed is also microorganisms capable of producing said compounds, compositions containing said compounds, and the use of such compositions for controlling fungi in valuable crops, animals, including birds and mammals, and in the preservation of wood, paints and edible products.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: April 25, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Ruby I. Nielsen, Frank W. Rasmussen
  • Dispenser for pills or tablets
    Patent number: 5405047
    Abstract: A dispenser for dispensing tablets one at a time from an unarranged stock of tablets in the dispenser. The dispenser comprises a first reservoir part axially displaceable in a second reservoir part against the force of a spring (4). A trough shaped part (5,6) at the inner end of the first part forms with a partition (13) at the bottom of the second part a downward closed channel accommodating at least two tablets when the dispenser is in its neutral position. When the dispenser is operated by forcing the first part further into the second part, a bottom (7) closing the channel is passed free of the partition (13) and the lowermost tablet is dispensed. At the same time two fingers (9) are passed into the space left at the sides of the channel between the lowermost tablet and the adjacent tablet above it to ensure that only the lowermost tablet is dispensed.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: April 11, 1995
    Assignee: Novo Nordisk A/S
    Inventor: Ib Hansen
  • Removal of printing paste thickener and excess dye after textile printing
    Patent number: 5405414
    Abstract: In textile printing using a printing paste containing a dye and a biological polymer (or modified polymer) as thickener, removal of the thickener and excess dye is made much more efficient by washing the printed textile in the presence of a suitable enzyme. The enzymatic breakdown of thickener decreases process time as well as the amount of energy and water needed to achieve a satisfactory quality of the textile.
    Type: Grant
    Filed: September 9, 1993
    Date of Patent: April 11, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Gitte Pedersen, Hans A. Hagen, Lars Asferg, Ebbe Sorensen